The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for chikungunya, a virus transmitted by mosquitoes.

See what infectious disease doctors have to say as government officials appear poised to scale back COVID vaccines and the FDA approved the Novavax vaccine with new limitations.

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) has officially approved a COVID-19 vaccine from Novavax for adults 65 and older and for individuals ages 12 to 64 who have an underlying health condition that puts them at higher risk for serious illness from a coronavirus infection.

The U.S. Centers for Disease Control and Prevention accepted its advisory panel's recommendations on vaccines for chikungunya, a mosquito-borne virus. The recommendations were approved on May 13, 2025,

"Here is a prime example of just how influential Big Pharma still is," MAHA influencer Diana Atieh told Newsweek.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy.

The Trump administration plans to drop routine COVID vaccination guidance for kids and pregnant women, marking a major shift in federal health policy, according to a report.

Secretary Robert F. Kennedy Jr., who leads the Department of Health and Human Services, will soon announce the changes to the vaccine schedule.